The ALS Research Study

Currently Recruiting

8 Jun 2026

Up to $2,550

Melbourne, Australia

The study drug is being developed as a new potential treatment for people living with amyotrophic lateral sclerosis (ALS), also known as motor neuron disease. ALS is a condition where nerve cells that control movement slowly stop working. In people with ALS, a protein called TDP‑43 builds up in clumps inside nerve cells, which is believed to damage them and make the disease worse.

The study drug is designed to break down these harmful protein clumps while leaving the normal protein alone. By doing this, the drug may help nerve cells work more normally and slow down damage over time.

This is a healthy volunteer study. Before a new treatment can be studied in people with ALS, it must first be carefully evaluated in healthy volunteers. This initial study helps researchers understand how the study drug behaves in the body, how it is processed, and whether it is safe and well tolerated. The information collected in healthy volunteers is an important step in supporting future studies in people living with ALS.

Apply now Speak with us 1300 491 746

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.

What to expect

  • Participation in a monitored clinical environment
  • Study visits scheduled
  • Support from a professional medical team
  • Reimbursement for your time and commitment

Trial details

Study duration

  • 3 nights stay
  • 1 follow-up visit

Study medication

Administered via an oral capsule or liquid.

Additional eligibility

• Weight between 50-110 kg
• Non-smokers or casual smokers of up to 5
cigarettes per week

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 65 years old

Remuneration

Up to $2,550 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

BMI

BMI 18 - 30 kg/m2

Commitment

3 nights, 1 clinic visit

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact